Notice Pursuant to the National Cooperative Research and Production Act of 1993-Cooperative Research Group on CHEDE-VII, 58653-58654 [2017-26890]

Download as PDF Federal Register / Vol. 82, No. 238 / Wednesday, December 13, 2017 / Notices sradovich on DSK3GMQ082PROD with NOTICES Commission Rule 210.2 (19 CFR 210.2), without a formal hearing or discovery. Epson filed a timely response opposing the request. Thereafter, Requesters filed a motion for leave to file a reply to Epson’s response. On June 16, 2017, the Commission determined to institute a consolidated advisory opinion proceeding in both investigations and referred the request to the Chief ALJ to designate a presiding ALJ. 82 FR 27723 (Jun. 16, 2017). Epson, the Requesters, and OUII were named as parties to the proceeding. The Commission also determined to deny Requesters’ motion for leave to file a reply. On November 17, 2017, Epson and the Requesters filed a joint motion to terminate the consolidated advisory opinion proceeding based on a settlement agreement. The joint motion included a confidential version of the settlement agreement. A public version of the agreement was filed with the public version of the joint motion. That same day, OUII filed a response in support of the joint motion. On November 22, 2017, the ALJ issued the subject ID (Order No. 6) granting the joint motion to terminate the consolidated advisory opinion proceeding. No petitions for review were filed. The Commission has determined not to review the subject ID. The Commission agrees with the ALJ that the joint motion to terminate the consolidated advisory opinion proceeding complies with the Commission’s rules for termination and that there is no evidence that termination of the proceeding will adversely affect the public interest. Order No. 6 at 2–3. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Dated: December 7, 2017. William R. Bishop, Supervisory Hearings and Information Officer. [FR Doc. 2017–26826 Filed 12–12–17; 8:45 am] BILLING CODE 7020–02–P VerDate Sep<11>2014 18:53 Dec 12, 2017 Jkt 244001 JUDICIAL CONFERENCE OF THE UNITED STATES Hearings of the Judicial Conference Advisory Committees on the Federal Rules of Appellate and Criminal Procedure and Rules of Evidence Advisory Committees on the Federal Rules of Appellate and Criminal Procedure, and Rules of Evidence, Judicial Conference of the United States. ACTION: Notice of cancellation of public hearings. AGENCY: The January 5, 2018 public hearings in Phoenix, Arizona, on proposed amendments to the Appellate, Criminal and Evidence Rules, the Rules Governing Section 2254 Cases in the United States District Courts, and the Rules Governing Section 2255 Proceedings for the United States District Courts have been canceled. FOR FURTHER INFORMATION CONTACT: Rebecca A. Womeldorf, Rules Committee Secretary, Rules Committee Staff, Administrative Office of the United States Courts, Washington, DC 20544, telephone (202) 502–1820. SUPPLEMENTARY INFORMATION: Announcement for this hearing was previously published in 82 FR 37610. SUMMARY: Dated: December 7, 2017. Rebecca A. Womeldorf, Rules Committee Secretary. 58653 Also, ArcSoft Inc., Freemont, CA; ASD Electronics, Kowloon, HONG KONG–CHINA; EDC GmbH, Langenhagen, GERMANY; Orion Electric Co., Ltd., Fukui, JAPAN; Pixela Corporation, Osaka, JAPAN; TEAC Corporation, Tokyo, JAPAN; and Yamaha Corporation, Hamamatsu, JAPAN, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and DVD CCA intends to file additional written notifications disclosing all changes in membership. On April 11, 2001, DVD CCA filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on August 3, 2001 (66 FR 40727). The last notification was filed with the Department on August 23, 2017. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on September 29, 2017 (82 FR 45611). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2017–26891 Filed 12–12–17; 8:45 am] BILLING CODE P [FR Doc. 2017–26789 Filed 12–12–17; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 2210–55–P Antitrust Division DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—DVD Copy Control Association Notice is hereby given that, on November 21, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), DVD Copy Control Association (‘‘DVD CCA’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Cinram GmbH, Oliphant, PA; Kaleidescape, Inc., Mountain View, CA; and Lite-On Technology Corp., Taipei, TAIWAN, have been added as parties to this venture. PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 Notice Pursuant to the National Cooperative Research and Production Act of 1993—Cooperative Research Group on CHEDE–VII Notice is hereby given that, on November 8, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Southwest Research Institute— Cooperative Research Group on CHEDE–VII (‘‘CHEDE–VII’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, General Motors, Detroit, MI, has withdrawn as a party to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research E:\FR\FM\13DEN1.SGM 13DEN1 58654 Federal Register / Vol. 82, No. 238 / Wednesday, December 13, 2017 / Notices project remains open, and CHEDE–VII intends to file additional written notifications disclosing all changes in membership. On January 6, 2016, CHEDE–VII filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on February 2, 2016, (81 FR 5484). The last notification was filed with the Department on February 13, 2017. A notice was published in the Federal Register pursuant to section 6(b) of the Act on March 27, 2017, (82 FR 15239). Patricia A. Brink, Director of Civil Enforcement, Antitrust Division. [FR Doc. 2017–26890 Filed 12–12–17; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: VHG Labs DBA LGC Standard Warehouse ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 12, 2018. Such persons may also file a written request for a hearing on the application on or before January 12, 2018. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrissette DATES: Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix of subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on April 4, 2017, VHG LABS DBA LGC Standards Warehouse, 3 Perimeter Road, Manchester, New Hampshire 03103 applied to be registered as an importer of the following basic classes of controlled substances: sradovich on DSK3GMQ082PROD with NOTICES Controlled substance Drug code 3-Fluoro-N-methylcathinone (3-FMC) .............................................................................................................................. Cathinone ........................................................................................................................................................................ Methcathinone ................................................................................................................................................................. 4-Fluoro-N-methylcathinone (4-FMC) .............................................................................................................................. Pentedrone (a-methylaminovalerophenone) ................................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................... 4-Methyl-N-ethylcathinone (4-MEC) ................................................................................................................................ Naphyrone ....................................................................................................................................................................... N-Ethylamphetamine ....................................................................................................................................................... N,N-Dimethylamphetamine .............................................................................................................................................. Fenethylline ..................................................................................................................................................................... 4-Methylaminorex (cis isomer) ........................................................................................................................................ Methaqualone .................................................................................................................................................................. Mecloqualone .................................................................................................................................................................. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) ................................................................................................... SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................. 5-Flouro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................. AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ...................... JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) ....................................................................................................................... ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) .................................. APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .............................................................. JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) ................................................................................................... SR-19 (Also known as RCS-4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole ...................................................................... JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ...................................................................................................... UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................. JWH-073 (1-Butyl-3-(1-naphthoyl)indole) ........................................................................................................................ JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) ........................................................................................... AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ....................................................................................................... JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ...................................................................................................... PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) .................................................................................................. 5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) .............................................................................. Alpha-ethyltryptamine ...................................................................................................................................................... Ibogaine ........................................................................................................................................................................... CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................. CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) ........................................... VerDate Sep<11>2014 18:53 Dec 12, 2017 Jkt 244001 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 E:\FR\FM\13DEN1.SGM 13DEN1 1233 1235 1237 1238 1246 1248 1249 1258 1475 1480 1503 1590 2565 2572 6250 7008 7011 7012 7019 7035 7048 7081 7104 7118 7122 7144 7173 7200 7201 7203 7222 7225 7249 7260 7297 7298 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I

Agencies

[Federal Register Volume 82, Number 238 (Wednesday, December 13, 2017)]
[Notices]
[Pages 58653-58654]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26890]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Cooperative Research Group on CHEDE-VII

    Notice is hereby given that, on November 8, 2017, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Southwest Research 
Institute--Cooperative Research Group on CHEDE-VII (``CHEDE-VII'') has 
filed written notifications simultaneously with the Attorney General 
and the Federal Trade Commission disclosing changes in its membership. 
The notifications were filed for the purpose of extending the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Specifically, General Motors, 
Detroit, MI, has withdrawn as a party to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research

[[Page 58654]]

project remains open, and CHEDE-VII intends to file additional written 
notifications disclosing all changes in membership.
    On January 6, 2016, CHEDE-VII filed its original notification 
pursuant to Section 6(a) of the Act. The Department of Justice 
published a notice in the Federal Register pursuant to Section 6(b) of 
the Act on February 2, 2016, (81 FR 5484).
    The last notification was filed with the Department on February 13, 
2017. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on March 27, 2017, (82 FR 15239).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-26890 Filed 12-12-17; 8:45 am]
 BILLING CODE P